title: Microcirculatory effects of Viatromb spray gel heparin in chronic venous insufficiency: evaluation of TcPO2 and PCO2--a product evaluation study.
abstract: The evolution of microcirculatory methods and the definition of the concept of venous microangiopathy allow the study in a quantitative way of microcirculatory changes produced by pharmacologic treatments at the areas most frequently and severely affected by chronic venous insufficiency (CVI), venous hypertensive microangiopathy, and venous ulcerations. This pilot study compares subjects with CVI, in the area most affected by venous hypertension in a 2-week registry. Elastic compression, compression plus Viatromb (lyposomal spray gel heparin), Lioton (gel including heparin), and Viatromb alone were compared. Subjects were evaluated for laser Doppler flux, transcutaneous partial pressure of oxygen (TcPO2), and partial pressure of carbon dioxide (PCO2) and CVI analogic symptom scale. In the Viatromb groups (B and D), significant decreases in laser Doppler flux, PCO2, and CVI score were observed. The decrease was proportionally more important in the elastic compression plus Viatromb group. Partial pressure of oxygen (PO2) was significantly increased. No significant changes were observed in the Lioton group. There was a good effect for compression only. These differences are significant, as they can be observed even in small groups (10-15 patients). No treatment side effects were observed, and compliance and tolerability were very good.
authors.affiliation: Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D'Annunzio, Chieti-Pescara University.
authors.forename: Maria
authors.initials: M
authors.lastname: Rosaria Cesarone
authors.forename: Gianni
authors.initials: G
authors.lastname: Belcaro
authors.forename: Silvia
authors.initials: S
authors.lastname: Errichi
authors.forename: Luciano
authors.initials: L
authors.lastname: Pellegrini
authors.forename: Andrea
authors.initials: A
authors.lastname: Ledda
authors.forename: Giulia
authors.initials: G
authors.lastname: Vinciguerra
authors.forename: Andrea
authors.initials: A
authors.lastname: Ricci
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Gizzi
authors.forename: Edmondo
authors.initials: E
authors.lastname: Ippolito
authors.forename: Filiberto
authors.initials: F
authors.lastname: Fano
authors.forename: Mark
authors.initials: M
authors.lastname: Dugall
authors.forename: Giovanni
authors.initials: G
authors.lastname: Acerbi
authors.forename: Marisa
authors.initials: M
authors.lastname: Cacchio
authors.forename: Andrea
authors.initials: A
authors.lastname: Di Renzo
authors.forename: Morio
authors.initials: M
authors.lastname: Hosoi
authors.forename: Stefano
authors.initials: S
authors.lastname: Stuard
authors.forename: Marcello
authors.initials: M
authors.lastname: Corsi
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D001785:Blood Gas Monitoring, Transcutaneous; D002908:Chronic Disease; D005260:Female; D005782:Gels; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D008081:Liposomes; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D053828:Stockings, Compression; D014647:Varicose Ulcer / Q000188:drug therapy*; D014689:Venous Insufficiency / Q000097:blood / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D005782:Gels; D008081:Liposomes; D006493:Heparin